Get all premium features to the best stock analysis tool

Finranks

Finranks

Company

  • About us

Contact us

  • [email protected]

Follow us

  • Instagram
  • Telegram
  • LinkedIn

All rights reserved.

Privacy PolicyTerms of Conditions
  • Home
  • Markets
  • Screener
  • News
  • About
  1. Home
  2. OCS
O

Oculis Holding AG (OCS)

NGM – Real Time Price. Currency in USD

24.69

-0.30 (-1.20%)

At close: Mar 27, 2026, 4:00 PM EDT

24.69

0.00 (0.00%)

After-hours: Mar 27, 2026, 5:20 PM EDT

  • Summary
  • News
  • Chart
  • Financial
  • Dividends
  • Forecast
  • Ownership
  • Profile

Stock details

Previous close
24.69CHF
Day's range
24.32 - 25.09CHF
52-week range
14 - 30.68CHF
Volume
126 145
Average volume
231 844
Beta
0.64
EPS (TTM)
-2.28
PE ratio (TTM)
N/A
Market cap
1 411 514 382
Shares outstanding
57 169 477
Dividend yield
N/A
Next earnings date
2026-05-07
Sector
Healthcare
Industry
Biotechnology

About the company

Oculis Holding AG, a clinical-stage biopharmaceutical company, develops drug candidates to treat ophthalmic, neuro-ophthalmic, and neurological diseases in Switzerland and internationally. The company’s lead product candidate is OCS-01, a topical dexamethasone optireach formulation, which is in Phase 3 clinical trials for the treatment of diabetic macular edema; OCS-02, a topical biologic candidate that is in Phase 2b clinica... read more
CEO
Riad Sherif
Country
Switzerland
IPO Date
Employees
49
Fiscal Year End
January - December
Website
https://oculis.com

Revenue Breakdown

No Data

Revenue breakdown data has not been calculated yet.

News

No Data

There are no news for this stock.

Chart: OCS

Loading Chart...

Overall Score

3 / 1030%
Financial Strength
8
Profitability
1
Effectiveness
1
Growth
4.2
Forecast
5.6
Valuation
2.1

Financial Strength

NAMERATIOINDUSTRY5Y TRENDSCORE
Current ratio5.966.0510
Quick ratio5.965.6310
Debt to Equity0.010.309.0
Debt to Assets0.011.0410
Interest coverage-87.32-16.911.0
Weighted average score8.0

Debt to Assets

Financial

Values in USD
(B=Billions, M=Millions, K=Thousands)
Values in USD (B=Billions, M=Millions, K=Thousands)
METRIC2022202320242025TTM
Total RevenueN/AN/AN/AN/AN/A
Gross Profit-313K-319K-461K-657K-462K
Operating Income-35M-52M-84M-100M-100M
Net Income-41M-99M-97M-119M-118M
EBITDA-35M-52M-83M-99M-100M

Current Ratio

Revenue & Net Income

Cashflow

Margin Ratios

Profitability

NAMERATIOINDUSTRY5Y TRENDSCORE
Gross margin %N/A-11.731.0
Operating margin %N/A-24.601.0
Net margin %N/A-172.201.0
EBITDA margin %N/A-201.271.0
Cash flow margin %N/A-156.391.0
Weighted average score1.0

Net Margin

Effectiveness

NAMERATIOINDUSTRY5Y TRENDSCORE
ROA-63.76-57.97
1.0
ROE-81.47-63.56
1.0
ROIC-80.77-42.57
1.0
ROCE-12.94-71.10
1.0
Weighted average score1.0

Estimated EPS vs Actual EPS

Forecast

NAMEREVENUE GROWTHEPS GROWTHSCORE
Current quarter-20.0835.015.5
Next quarter-21.7911.834.0
Current year338.957.247.5
Next year529.63-5.795.5
Weighted average score5.6

Analyst Rating

Growth

NAMEREVENUENET INCOMEEPSFCFSCORE
Q/Q999-39.67-31.86-12.143.3
Y/Y9999.9128.19-89.276.8
3y average999-54.9121.38-54.525.5
5y averageN/AN/AN/AN/A1.0
Weighted average score4.2

Revenue Growth Rate vs. Industry

Valuation

NAMERATIOINDUSTRY5Q TRENDSCORE
P/E63.97-5.25
3.0
PEG (5yr expected)N/A0.27
1.0
P/SN/A64.66
1.0
P/B5.832.96
3.2
Weighted average score2.1

DCF Model

DCF Model PeriodN/A
Discount rateN/A
Perpetual growth rateN/A
Revenue 5 year CAGRN/A
FCF 5 year CAGRN/A
Fair value$
Stock price24.69$

Dividend

NAMECURRENTINDUSTRYSCORE
Dividend yield0.00N/A1.0
Payout ratio0.00N/A1.0
5-year dividend growth rateN/AN/A1.0
Years of dividend increaseN/AN/A1.0
Weighted average score1.0

Fair Value

Fair Value

$1

UndervaluedStock priceOvervalued

$24.69

Economic Moat

NAMESCALESCORE
Market shareNone1.0
Intangible assetsNone1.0
Switching costsNone1.0
Network effectNone1.0
Economies of scaleNone1.0
Weighted average score1.0
Dividend
1
Economic Moat
1

Octagon View

Strength & Weakness

Company's cash reserves $102.7M significantly exceed its total debt $2.9M, ensuring strong financial flexibility

Total current assets $276.3M exceed Total current liabilities $46.4M, highlighting excellent liquidity

Debt-to-equity ratio (0.0) is well below the industry average (0.3), showcasing prudent financial management

Interest coverage ratio (-87.3x) is dangerously low, suggesting debt repayment risks

Negative free cash flow -$20.2M limits the company's ability to reinvest or pay down debt